2022 TTS Recognition Award Winners Announced!

Professor Angus W. Thomson
United States
Professor Denis Glotz
Professor Elaine Reed
United States
Professor Vivek Kute

About the Awards

These awards recognize individuals who have made a major international impact in the field of transplantation. The award winners will be honored during the President's Plenary session on Wednesday, September 14, 2022.

In Memoriam - Anthony Peter "Tony" Monaco (1932 - 2022)

Anthony P. Monaco

Anthony Monaco was a TTS Past-President, a Medawar Prize Laureate, a pioneer and a friend to all.

Beloved Husband and Father, Pioneering Transplant Surgeon and Scientist Teacher, Mentor, Collaborator, and Friend to Many, Peter Medawar, Professor of Surgery Emeritus at Harvard Medical School, and Director Emeritus of the Division of Transplantation at Beth Israel Deaconess Medical Center, died peacefully on August 22, with his family by his side.
Visit Anthony Monaco's Page on TTS.org with some articles, videos and his Medawar Prize acceptance speech.

TTS 2022 In-Person Online Registration Closes August 28!

You can now browse the detailed program and see who is presenting at TTS 2022. If you plan to attend virtually you can view the schedule in your local time zone.

Register to the Congress

In-Person Online registration closes on August 28
(You can still register in-person onsite from 2 pm on September 10).

Virtual Registration will remain open during the entire duration of the congress.

Hotel reservations are available here - Book early as space is limited!

Transplantation Updates

Transplantation - September Issue

This issue starts with a detailed examination of donor issues - including cancer transmission in Spain and several papers on perfusion to improve outcomes in heart, liver and kidney transplantation. The critical issue of artificial resumption of circulation during donation DCD is elegantly presented and discussed. Several articles present the current-day issues in Xenotransplantation - all cause for thought. COVID remains at the top of many people's agendas in transplantation, despite the waning interest in the general community, because of the important adverse outcomes in transplant recipients. There are several useful papers on COVID issues to keep us all abreast of the knowledge.

Table of Contents

Around the World

People in Transplantation

Research Highlights

Special Article

Expert Insight


Transplantation - Week's Most Downloaded Paper

GFR Assessment of Living Kidney Donors Candidates

Living kidney donation provides the best outcomes (survival, cost, and quality of life) of all renal replacement modalities. Living kidney donors, on the other hand, are at an increased risk of end-stage kidney disease (ESKD) after donation compared with healthy nondonors for multiple reasons. Extensive pre-donation screening is required to assess eligibility for donation to avoid the rejection of suitable candidates and minimize the acceptance of donors with an increased risk of ESKD.

Transplantation Direct - Highlighted Tweet

Heart Transplantation, Either Alone or Combined With Liver and Kidney, a Viable Treatment Option for Selected Patients With Severe Cardiac Amyloidosis

Heart transplantation in cardiac amyloidosis (CA) patients is possible and generally considered for transplantation if other organs are not affected. In this study, we aimed to describe and assess outcomes in patients following heart transplantations at our CA referral center.

News Spotlight

Researchers have been able to alter the blood type of deceased donor kidneys using “molecular scissors”.
The discovery offers hope to ethnic minority patients who struggle to find suitable transplants.

Researchers at the University of Cambridge have successfully altered the blood type on three deceased donor kidneys in a ground-breaking discovery that could have major implications for kidney patients.

The project, funded by charity Kidney Research UK, could increase the supply of kidneys available for transplant, particularly within ethnic minority groups who are less likely to be a match for the majority of donated kidneys.

Professor Mike Nicholson and PhD student Serena MacMillan used a normothermic perfusion machine – a device which connects with a human kidney to pass oxygenated blood through the organ to better preserve it for future use – to flush blood infused with an enzyme through the deceased kidney.

The enzyme acted like “molecular scissors” to remove the blood type markers that line the blood vessels of the kidney resulting in the organ being converted to the most common O type.  

A kidney from someone with an A blood type cannot be transplanted to someone with a B blood type, nor the other way around. But changing the blood type to the universal O will allow more transplants to take place as O can be used for people with any blood group.

Hot Off The Press


Compiled and Edited by Enver Akalin
TTS Educational Committee started weekly Hot Off the Press in April 2020, after the COVID-19 pandemic, to review important articles related to COVID-19 and transplantation. The aim was to inform the TTS members of important publications as early as possible, and this initiative has received good feedback. We plan to continue New Hot Off The Press to cover various other topics on a weekly basis and pick up the crucial manuscripts published in high impact journals.
Tissue Typing and Pathology

The MHC class I MICA gene is a histocompatibility antigen in kidney transplantation

Raphael Carapito et al.
Nat Med. 2022 May;28(5):989-998. doi: 10.1038/s41591-022-01725-2 PMID: 35288692
This study investigated the role of MICA in allograft survival in a French multicenter cohort of 1,356 kidney transplants. MICA mismatches were associated with decreased graft survival (HR, 2.12; 95% CI: 1.45-3.11; P < 0.001). Both before and after transplantation anti-MICA donor-specific antibodies (DSA) were strongly associated with increased antibody-mediated rejection (ABMR) (HR, 3.79; 95% CI: 1.94-7.39; P < 0.001; HR, 9.92; 95% CI: 7.43-13.20; P < 0.001, respectively). This effect was synergetic with that of anti-HLA DSA before and after transplantation (HR, 25.68; 95% CI: 3.31-199.41; P = 0.002; HR, 82.67; 95% CI: 33.67-202.97; P < 0.001, respectively). De novo-developed anti-MICA DSA were the most harmful because they were also associated with reduced graft survival (HR, 1.29; 95% CI: 1.05-1.58; P = 0.014). Finally, the damaging effect of anti-MICA DSA on graft survival was confirmed in an independent cohort of 168 patients with ABMR (HR, 1.71; 95% CI: 1.02-2.86; P = 0.041). In conclusion, assessment of MICA matching and immunization for the identification of patients at high risk for transplant rejection and loss is warranted.
Tissue Typing and Pathology

Association of Predicted HLA T-Cell Epitope Targets and T Cell-Mediated Rejection After Kidney Transplantation

Aleksandar Senev et al.
Am J Kidney Dis. 2022 Jun 8:S0272-6386(22)00708-9.
doi: 10.1053/j.ajkd.2022.04.009 PMID: 35690154
This is a retrospective cohort study of 893 kidney transplant recipients between 2004-2013 with available biopsy data and a DNA sample for high-resolution HLA donor/recipient typing to investigate the relationship between HLA molecular mismatches and T-cell mediated rejection (TCMR). 277 patients developed TCMR and 134 developed only borderline changes suggestive of TCMR on at least one biopsy. In multivariable analyses, only the PIRCHE-II scores (Predicted Indirectly ReCognizable HLA Epitopes by recipient HLA class II molecules algorithm) for HLA-DRB1 and HLA-DQB1 were independently associated with the occurrence of TCMR and with allograft failure; this was not the case for HLA class I molecules. If restricted to rejection episodes within the first 3 months after transplantation, only the T-cell epitope targets originating from the donor's HLA-DRB1 and HLA-DQB1, but not class I molecules, were associated with the early acute TCMR. Also, the median number of PIRCHE-II scores for HLA class II was statistically different between the patients with TCMR compared to the patients without TCMR (129, IQR=60-240; vs. 201, IQR=96-298; p<0.0001, respectively). These differences were not observed for class I PIRCHE-II scores.

TTC Public Workshop - September 22, 2022 @ 8AM ET

Since 2017 TTS has been participating in the Transplantation Therapeutics Consortium (TTC), a program of the Critical Path Institute.

Accelerating medical product development in kidney transplantation through a public-private partnership

This public workshop will focus on 1) qualifying a composite surrogate for long-term graft loss after kidney transplantation 2) real-world evidence (RWE) use in transplant clinical trials and 3) potential future endpoints in kidney transplantation The Transplant Therapeutics Consortium (TTC) aims to accelerate the medical product development process for transplantation by identifying challenges, prioritizing solutions, and developing tools to advance new product development to meet the most pressing needs of transplant recipients.
Click to view the agenda
Welcoming remarks
Session 1: Qualifying a composite surrogate for long-term graft loss after kidney transplantation
  • Regulatory qualification procedures and qualification status of the iBox Scoring System as a reasonably likely surrogate endpoint with FDA
  • Graphical user interface for sample size calculation using iBox scores
  • Panel discussion
Session 2: RWE use in transplant clinical trials
  • Regulatory and design considerations for RWE supplementation in transplant clinical trials
  • Pilot study for external control using the cyclosporine arm of the BENEFIT RCT versus UNOS/OPTN registry data
  • Sample size calculation and use RWE for supplemental external controls for the 5-year survival analyses
  • Panel discussion
Session 3: Future endpoints in kidney transplantation
  • Efficacy endpoints
  • Safety endpoints
  • Regulatory qualification procedures for clinical outcome assessments
  • Patient-reported outcome measures for transplantation
  • Panel discussion
Closing Remarks

Upcoming Webinar: TID - Clinicopathologic Conference Series Continues!

TTS Needs Assessment Survey

This survey focuses on issues encountered by physicians in day-to-day decision-making.

Your responses will aid TTS in developing strategies, programs and resources to improve access and transparency in transplantation, emphasizing increasing deceased donor organ transplantation.

The information collected will also aid the work TTS is doing as part of our World Health Organization collaboration.

All responses will be kept confidential and anonymous.

The survey will take 6+ minutes and must be done from a computer or tablet.

In the News 



Staff Directory


The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6